Remove 2029 Remove Communication Remove Labelling
article thumbnail

NHC Submits Comments on FDA’s Draft Guidance for Voluntary Incorporation of Patient Preference Information

Putting Patients First Blog

Real-world case studies demonstrating how PPI has influenced decisions, such as targeted approvals or label modifications, would clarify its practical utility. 17 In addition to its role in pre-market decisions, PPI can be valuable in post-market activities, including the formulation and communication of recall notices. 1 (2009): 2029.

article thumbnail

Vetter breaks ground on $285m US clinical manufacturing site

Pharmaceutical Technology

The facility will be complete and ready for media fill by late 2029, with plans to move Vetter’s existing clinical operations in Skokie. How will RFK Jr’s American dream for vaccines play out? The planned 160,000ft² facility will focus on aseptic production and includes areas for material preparation and compounding.

article thumbnail

EHA 2025: AstraZeneca’s surovatamig is potential next-gen BiTE for R/R B-ALL

Pharmaceutical Technology

At the 2025 Congress of the European Hematology Association (EHA 2025), held from 12 June 12 to 15 June in Milan, Italy, preliminary dose-escalation and optimisation results from the global, multicentre, open-label, single-arm Phase I/II SYRUS clinical trial (NCT06137118) were presented on the second day.